I agree. I guess whether it represents an opportunity or not is in the eye of the beholder.
Sifting through all the noise and rumour, it seems obvious to me that the increased marketing expenditure has been the main catalyst for the drop.
It is my view that only the upfront $$$ costs of that investment have been factored in, and not the dividends in terms of sustainable, long-term growth and market share.
- Forums
- ASX - By Stock
- A2M
- Media Updates
Media Updates, page-3191
-
-
- There are more pages in this discussion • 11,283 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$6.88 |
Change
0.000(0.00%) |
Mkt cap ! $4.973B |
Open | High | Low | Value | Volume |
$6.90 | $6.90 | $6.80 | $7.266M | 1.060M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12501 | $6.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.88 | 33092 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 292 | 6.840 |
2 | 8043 | 6.820 |
1 | 500 | 6.810 |
1 | 1100 | 6.800 |
2 | 9844 | 6.750 |
Price($) | Vol. | No. |
---|---|---|
6.880 | 23244 | 1 |
6.900 | 7848 | 10 |
6.910 | 1515 | 1 |
6.920 | 20500 | 2 |
6.950 | 17350 | 9 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
A2M (ASX) Chart |